Enzalutamide

Form: Tablet & Capsule

Strength: Capsules- 40 mg, Tablet - 40 mg & 80 mg

Reference Brands: Xtandi® (EU & US)

Category: Oncology Cancer Care

Enzalutamide is a next-generation androgen receptor inhibitor indicated for the treatment of prostate cancer, including metastatic castration-resistant and non-metastatic castration-resistant forms. Marketed as Xtandi®, it is available in 40 mg capsules and 40 mg/80 mg tablets in both the US and EU. It works by blocking androgen signaling pathways, helping slow disease progression. With proven clinical benefits and oral administration, Enzalutamide represents a high-value B2B oncology opportunity for pharmaceutical partners targeting the oncology segment in regulated markets such as the EU and United States.